Primary Category:
Radiation Oncology
Disease Category:
Genitourinary, Prostate
Status:
Open
Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (with Initial Phase I)
NCT#04037254
GU007 is reopened to accrual to phase I/dose level 3, effective March 24, 2023.
GU007 Phase II is not open to accrual as of January 27, 2022.
